Lentiviruses and Lentiviral Vectors: Engineering from Natural Viruses to Gene Delivery Tools
Lentiviruses and Lentiviral Vectors: Engineering from Natural Viruses to Gene Delivery Tools
Natural lentiviruses are a category of retroviruses (e.g., HIV-1) characterized by chronic infection and inherent pathogenicity. In contrast, lentiviral vectors are engineered, safety-modified tools derived from natural lentiviruses. By removing pathogenic genes while retaining efficient gene delivery capabilities, they have been transformed into versatile research and clinical vectors with broad host tropism and stable long-term expression. They are now widely applied in fields such as cellular function studies and CAR-T cell therapy.
I. Biological Basis of Natural Lentiviruses
1.1 Definition and Classification of Natural Lentiviruses
Natural lentiviruses belong to the Retroviridae family. Their genome consists of single-stranded positive-sense RNA, and their life cycle crucially involves reverse transcription and genomic integration. The most prominent biological feature of lentiviruses is the significant temporal delay in their infection process. Following host entry, they typically do not cause rapid acute cytopathic effects but gradually impact host cell function and organismal homeostasis through long-term, persistent replication and immune modulation, thus classifying them as "chronic infection-type viruses."
(1) Common Types of Natural Lentiviruses
Well-studied natural lentiviruses primarily include Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 2 (HIV-2), as well as Simian Immunodeficiency Virus (SIV) infecting non-human primates and Feline Immunodeficiency Virus (FIV) infecting felines. These viruses share high conservation in genomic structure and replication strategies. HIV-1, due to its public health importance and extensive molecular biology research foundation, has become the primary prototype for subsequent engineering of lentiviral vectors.
(2) Pathogenicity of Natural Lentiviruses
Represented by HIV-1, natural lentiviruses possess clear pathogenic potential. By infecting immune-related cells such as CD4⁺ T lymphocytes, macrophages, and dendritic cells, they progressively impair host immune response, ultimately leading to Acquired Immunodeficiency Syndrome (AIDS). This pathogenicity stems not from a single factor but is the combined result of long-term interactions between viral structural/regulatory proteins and the host immune system. Multiple viral accessory genes are involved in regulating replication efficiency, intracellular RNA transport, and host antiviral responses, which is the fundamental reason why natural lentiviruses cannot be directly applied in experimental or therapeutic settings.
1.2 Infection and Replication Mechanisms of Natural Lentiviruses
The lentiviral replication cycle is highly dependent on host cell machinery, and its infection process provides the molecular basis for chronic latency. The entire life cycle can be summarized as sequential steps: receptor binding, reverse transcription, integration, expression, and budding/release.
(1) Receptor Binding and Viral Entry
The envelope glycoprotein complex on the surface of HIV-1 virions, composed of gp120 and gp41, initiates infection. Gp120 first recognizes and binds the host cell surface receptor CD4. Subsequent conformational changes allow interaction with a co-receptor, CCR5 or CXCR4. This multi-step binding process ultimately triggers gp41-mediated fusion of the viral envelope with the cell membrane, allowing the viral core to enter the cytoplasm.
(2) Reverse Transcription and Genomic Integration
Following entry, the viral core partially uncoats in the cytoplasm. Reverse transcriptase synthesizes double-stranded DNA using the viral RNA as a template. This DNA, along with integrase and various viral and host proteins, forms the pre-integration complex, which is actively transported into the nucleus. Integrase catalyzes the insertion of viral DNA into the host chromosome, forming a stable proviral structure. This integration is the key molecular basis for the long-term persistence of lentiviruses within host cells and their propagation during cell division.
(3) Viral Expression and New Particle Release
Once integrated, the provirus utilizes the host transcriptional machinery to produce viral RNAs and proteins. These components assemble into new viral particles near the cell membrane and are released via budding from the cell surface, completing one replication cycle.
II. Engineering and Construction Principles of Lentiviral Vectors
The pathogenicity of natural lentiviruses limits their utility. Therefore, researchers have developed "lentiviral vectors" through targeted genetic modification—retaining the efficient gene delivery advantages of natural lentiviruses while eliminating pathogenicity, creating safe laboratory tools.
2.1 Core Engineering Strategy for Lentiviral Vectors
The core strategy is "removing pathogenic elements while retaining functional elements," specifically including:
(1) Deleting Pathogenic Genes: This involves the removal of virulence genes from the natural lentiviral genome. Key deletions include nef (which downregulates host CD4 and MHC class I molecules to aid immune evasion), tat (a transactivator of viral transcription), and vif (which inhibits the host antiviral protein APOBEC3G). This process effectively disables the virus's pathogenic functions and its ability to evade the host immune system.
(2) Engineering Replication Deficiency: Separating viral replication-essential genes (e.g., gag, pol, rev) from the vector genome and placing them onto helper plasmids. The lentiviral vector itself carries only the gene of interest and packaging signals. This "self-inactivating" design ensures the vector can complete only one round of gene delivery without autonomous replication or spread.
(3) Replacing the Envelope Protein: Substituting the natural lentiviral envelope protein (e.g., HIV-1's gp120) with the Vesicular Stomatitis Virus G glycoprotein (VSV-G). VSV-G does not utilize a single, specific receptor; instead, it interacts broadly with lipid components (such as phosphatidylserine) and receptors (e.g., members of the low-density lipoprotein receptor family) present on the surface of most mammalian cells. This promiscuous interaction triggers viral endocytosis and is the primary reason for the significantly broadened host range of VSV-G-pseudotyped lentiviral vectors.
2.2 Plasmid System for Lentiviral Vectors
Current systems commonly use a "three-plasmid" or "four-plasmid" system for lentiviral vector packaging. The functions of each plasmid are as follows:
(1) Transfer Plasmid: The core plasmid of the lentiviral vector, containing: ① Long Terminal Repeats (LTRs) regulating transcription; ② Packaging signal (Ψ) guiding virion assembly; ③ The exogenous gene of interest (e.g., therapeutic gene, reporter gene); ④ A selectable marker gene (e.g., antibiotic resistance gene for subsequent selection).
(2) Helper Plasmid(s): Provide structural proteins required for viral assembly, encoding Gag (core proteins), Pol (reverse transcriptase and integrase), and Rev (regulates nuclear export of viral RNA).
(3) Envelope Plasmid: Encodes the VSV-G envelope protein, determining viral host range and infectivity.
III. Core Biological Characteristics of Lentiviral Vectors
Engineered lentiviral vectors inherit the advantages of natural lentiviruses while possessing the safety and stability required for laboratory tools. Their core characteristics are as follows:
3.1 Broad Host Range
Lentiviral vectors can efficiently infect both dividing and non-dividing cells, covering the vast majority of experimental cell types, including:
(1) Tumor cell lines: e.g., HeLa, A549 lung carcinoma, HepG2 hepatocellular carcinoma.
(2) Primary cells: e.g., primary hepatocytes, cardiomyocytes, neurons.
(3) Stem cells: e.g., embryonic stem cells, mesenchymal stem cells, hematopoietic stem cells.
The ability to infect non-dividing cells stems from the capacity of the lentiviral pre-integration complex (containing DNA and viral proteins) to enter the nucleus through the nuclear pore complex, without relying on nuclear envelope breakdown during cell division (a capability absent in simple retroviruses).
3.2 Stable Transgene Expression
The RNA genome of the lentiviral vector is reverse-transcribed into double-stranded DNA upon host cell entry. Subsequently, integrase facilitates the random, high-frequency integration of this DNA into the host cell's chromosomes. This means the transgene replicates along with the host chromosome during cell division. Even after multiple cell passages, the transgene is not lost, enabling stable expression for months or even years. This makes lentiviral vectors the tool of choice for constructing stable cell lines.
3.3 Safety and Biocompatibility
(1) Non-pathogenic: Lentiviral vectors employ a "self-inactivating, replication-deficient" design, retaining only elements essential for gene delivery and carrying no pathogenic genes. No pathogenicity has been observed in laboratory use or clinical applications to date.
(2) Low Immunogenicity: The VSV-G envelope protein has relatively low immunogenicity. Lentiviral vector particles injected in vivo are less likely to trigger strong adaptive immune responses (e.g., antibody production, T-cell activation), allowing for sustained long-term gene expression, suitable for long-term experiments in animal models like mice and rats.
3.4 Transgene Capacity and Flexibility
The transgene capacity of lentiviral vectors is approximately 8 kb (including the gene of interest and regulatory elements), sufficient for most experimental needs. Furthermore, flexibility can be enhanced by modifying LTR sequences or incorporating inducible promoters (e.g., Tet-On system) to achieve "inducible expression" of the transgene.
IV. Packaging, Concentration, and Storage of Lentiviral Vectors
The application of lentiviral vectors requires a process of "packaging - concentration - storage," where operational details at each stage directly impact vector titer and activity.
4.1 Packaging Protocol for Lentiviral Vectors
The core of packaging involves using 293T cells (human embryonic kidney cells, chosen for high transfection efficiency and high viral yield) to express viral components and assemble particles. Specific steps:
(1) Cell Preparation: Seed 293T cells in the logarithmic growth phase into culture dishes. Culture until cells reach 70%-80% confluence (optimal cell state for highest transfection efficiency).
(2) Plasmid Transfection: Use a lentiviral packaging-specific transfection reagent (e.g., S1505995) to co-transfect the transfer plasmid, helper plasmid(s), and envelope plasmid into 293T cells. The transfection reagent facilitates plasmid passage through the cell membrane, enhancing transfection efficiency.
(3) Supernatant Collection: 48-72 hours post-transfection, viral particles are secreted into the cell culture supernatant. Collect the supernatant at this time (avoiding contamination with cell debris).
4.2 Concentration of Lentiviral Vectors
The titer in the collected supernatant is typically low (~10⁶-10⁷ TU/mL). Concentration is necessary to increase the titer. A common method is ultracentrifugation: mix the supernatant with a lentivirus concentration reagent (5×) (e.g., S1506239) in the appropriate ratio, incubate at 4°C, then centrifuge at high speed (e.g., 100,000 × g for 2 hours). Discard the supernatant and resuspend the viral pellet in a small volume of medium. The titer can thereby be increased to 10⁸-10⁹ TU/mL, meeting most experimental requirements.
4.3 Stable Storage of Lentiviral Vectors
Lentiviral vector activity is sensitive to temperature and freeze-thaw cycles. Therefore, using a lentivirus stabilization storage solution (e.g., L1505998) is recommended for long-term preservation. This solution typically contains components such as serum, glycerol, or specialized protein stabilizers, which help maintain the integrity of the viral envelope and overall particle stability. The concentrated virus should be mixed with the storage solution, aliquoted into small working volumes, and stored at -80°C. Under these conditions, lentiviral vectors can maintain stable titers for over 6 months. It is crucial to avoid repeated freeze-thaw cycles to prevent significant loss of infectivity.
V. Infection and Transgene Expression Process of Lentiviral Vectors
After entering target cells, lentiviral vectors undergo a series of molecular processes to achieve transgene expression, as detailed below:
5.1 Molecular Mechanism of Infection
(1) Viral Attachment and Entry: The VSV-G envelope protein on the lentiviral vector surface binds to phosphatidylserine on the target cell membrane, triggering envelope-cell membrane fusion. The viral core particle (containing the RNA genome, reverse transcriptase, etc.) enters the cytoplasm.
(2) Reverse Transcription and Nuclear Transport: Reverse transcriptase within the viral core synthesizes double-stranded DNA from the RNA template. This DNA, along with integrase and other proteins, forms the "pre-integration complex," which enters the nucleus via the nuclear pore (this step can occur in non-dividing cells with intact nuclear membranes).
5.2 Genomic Integration and Expression
(1) Genomic Integration: Integrase recognizes specific sequences in the host chromosome and catalyzes the random insertion of lentiviral DNA, forming a stable "proviral genome."
(2) Transgene Expression: The host cell's RNA polymerase binds to the promoter within the proviral LTR, transcribing mRNA for the gene of interest. This mRNA is transported to the cytoplasm and translated into the target protein. Expression of the target protein is typically detectable 48-72 hours post-infection and persists through cell passaging.
5.3 Role of Transduction Enhancers
Using a viral transduction enhancer (e.g., V1501911) can improve infection efficiency. It works by altering cell membrane permeability and/or inhibiting host cell antiviral pathways (e.g., IFN pathway), helping viral particles enter cells more efficiently and complete gene delivery. It is particularly useful for difficult-to-transduce cell types like primary cells.
VI. Primary Application Areas of Lentiviral Vectors
Leveraging their core advantages, lentiviral vectors have become essential tools in basic research, drug discovery, and clinical translation. Representative applications include:
6.1 In Vitro Cellular Function Studies
(1) Stable Cell Line Generation: Deliver a gene of interest (e.g., oncogene, tumor suppressor gene) via lentiviral vector into cells, followed by antibiotic selection to obtain stably expressing clones. For example, delivering mutant EGFR genes into lung adenocarcinoma cell lines to construct drug resistance models for studying resistance mechanisms.
(2) Gene Function Validation: Deliver small interfering RNA (siRNA) or CRISPR/Cas9 components via lentiviral vectors to achieve targeted gene knockdown or knockout. Observing subsequent changes in cell proliferation, invasion, apoptosis, etc., helps elucidate gene function.
6.2 In Vivo Animal Model Construction
(1) Tumor Model Engineering: Directly inject lentiviral vectors into tumor tissues in mice to deliver fluorescent reporter genes (e.g., Luciferase), enabling real-time monitoring of tumor growth and metastasis via live imaging. Therapeutic genes can also be delivered to observe their inhibitory effects on tumors.
(2) Tissue-Specific Gene Expression: By engineering the vector's promoter (e.g., liver-specific ALB promoter), transgene expression can be restricted to specific tissues (e.g., liver), facilitating the study of organ-specific diseases like hepatitis or liver fibrosis.
6.3 Clinical Translation Applications
(1) CAR-T Cell Therapy: Lentiviral vectors are currently a core tool in CAR-T therapy. The chimeric antigen receptor (CAR) gene is delivered into a patient's T lymphocytes via lentiviral vector, enabling T cells to express the CAR and specifically recognize tumor cells (e.g., CD19-positive B-cell lymphomas). Currently, CD19 CAR-T therapy is approved for treating relapsed/refractory B-cell leukemia, with its safety and efficacy validated clinically.
(2) Gene Therapy: For monogenic inherited disorders (e.g., sickle cell disease), lentiviral vectors are used to deliver functional copies of the normal gene into a patient's hematopoietic stem cells. Upon reinfusion, these cells can produce the normal protein long-term, alleviating disease symptoms.
VII. Related Aladdin Products
Product Number | Name | Application |
Lentivirus Concentration Reagent (5×) | Concentrate lentiviral particles and increase viral titer | |
Lentivirus Packaging Kit | Construct recombinant lentiviral particles (includes core packaging components) | |
Lentivirus Stabilization Storage Solution | Store lentiviruses to maintain their activity and infection efficiency | |
Viral Transfection Enhancer | Improve transfection efficiency of lentiviruses into hard-to-transfect cells | |
Specialized Transfection Reagent for Lentivirus Packaging | Mediate co-transfection of packaging plasmids to enhance virus packaging efficiency |
In summary, lentiviral vectors exemplify a paradigm shift in virology—transforming a dangerous pathogen into a powerful and safe gene delivery tool through precise molecular engineering. Their unique biological properties, such as the ability to infect non-dividing cells and achieve stable genomic integration, render them indispensable in fundamental research, disease modeling, and clinical gene therapy. From dissecting gene function in the laboratory to enabling revolutionary CAR-T cell therapies in the clinic, lentiviral vectors continue to propel advancements in life sciences and medicine. Looking forward, with further optimization of vector technology (e.g., improved targeting specificity and regulatory control), lentiviral vectors hold promising potential for broader therapeutic applications, enabling safer and more precise genetic interventions for a wide range of diseases.
Aladdin: https://www.aladdinsci.com/